Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Up 7,746.9% in January

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 5,022 shares, an increase of 7,746.9% from the January 15th total of 64 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 209,694 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 209,694 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Enzon Pharmaceuticals Stock Performance

OTCMKTS ENZN opened at $0.06 on Thursday. Enzon Pharmaceuticals has a one year low of $0.03 and a one year high of $0.17. The stock has a 50-day moving average of $0.05 and a 200 day moving average of $0.06. The company has a market capitalization of $4.75 million, a price-to-earnings ratio of -1.28 and a beta of 0.20.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.